NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




Cancer Control Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

 

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.



Any Site

Alliance A221602 - "Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial."

CANCER TYPE: Any Site
RESEARCH BASE: Alliance
NCT NUMBER: NCT03578081
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 02/20/2019 (22:35:07)

BRIEF DESCRIPTION

CINV prevention for patients to be treated with HEC or AC, Olanzapine +/- Fosaprepitant, any stage disease.  DCP-001 eligible.






DCP-001 -"Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)"

CANCER TYPE: Any Site
RESEARCH BASE: NCI
NCT NUMBER:
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 03/05/2019 (21:47:21)

Additional Consent Form: VIEW CONSENT FORM 2
UPDATED ON 03/05/2019 (22:01:53)

Additional Consent Form: VIEW CONSENT FORM 3
BRIEF DESCRIPTION

Collect expanded demographic and clinical data (e.g., socio economic situation, co-morbidities, method of diagnosis) across the NCORP network to help identify and best characterize patients that are screened but not enrolled and for patients that participate in NCI trials, to understand how these variables may impact outcomes.






SWOG S1614 - "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors."

CANCER TYPE: Any Site
RESEARCH BASE: SWOG
NCT NUMBER:
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 02/26/2019 (16:37:22)

Additional Consent Form: VIEW CONSENT FORM 2
UPDATED ON 02/26/2019 (16:37:22)

BRIEF DESCRIPTION

Prophylactic antiviral therapy (Tenofovir) for current or past HBV patients with stage I-III solid tumor malignancy, no primary liver ca, planned cytotoxic, immunotherapy, or targeted therapy.






Brain/CNS
Breast

Alliance A011104 - "EFFECT OF PREOPERATIVE BREAST MRI ON SURGICAL OUTCOMES, COSTS AND QUALITY OF LIFE OF WOMEN WITH BREAST CANCER"

CANCER TYPE: Breast
RESEARCH BASE: Alliance
NCT NUMBER: NCT01805076
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 11/30/2018 (19:53:06)

BRIEF DESCRIPTION

Breast ca, stage I-II, elig for BCT, compare local recurrence rates following BCT using preop staging w/mammography + MRI vs mammography only.  DCP-001 Eligible






Alliance A171601 - "A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer."

CANCER TYPE: Breast
RESEARCH BASE: Alliance
NCT NUMBER: NCT03633331
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 10/04/2018 (16:51:51)

BRIEF DESCRIPTION

Stage IV breast ca, ER+, Her2-, 70 or older, Palbociclib + Letrozole or Fulvestrant. DCP-001 eligible.






Alliance A221405 - "A STUDY EVALUATING THE PREGNANCY OUTCOMES AND SAFETY OF INTERRUPTING ENDOCRINE THERAPY FOR YOUNG WOMEN WITH ENDOCRINE RESPONSIVE BREAST CANCER WHO DESIRE PREGNANCY (POSITIVE)"

CANCER TYPE: Breast
RESEARCH BASE: Alliance
NCT NUMBER: NCT02308085
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
Patient Brochure: VIEW PATIENT BROCHURE
UPDATED ON 07/27/2018 (16:45:32)

BRIEF DESCRIPTION

Cancer control, pregnancy outcomes, stage I-III, ER+ and/or PR+ breast ca, endocrine therapy interruption after having completed between ≥ 18 months and ≤ 30 months, up to 2 years interruption to allow pregnancy, delivery, breastfeeding or failure to conceive.  DCP-001 Eligible






ECOG-ACRIN EA1151 - "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)"

CANCER TYPE: Breast
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT03233191
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 01/31/2019 (19:09:07)

BRIEF DESCRIPTION

Cancer control, women 45-74, screening mammogram, digital mammography vs. tomosynthesis.  DCP-001 Eligible






NRG-CC004 - "PHASE II DOUBLE BLIND DOSE FINDING TRIAL OF BUPROPION VERSUS PLACEBO FOR SEXUAL DESIRE IN WOMEN WITH BREAST OR GYNECOLOGIC CANCER"

CANCER TYPE: Breast
RESEARCH BASE: NRG
NCT NUMBER: NCT03180294
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 03/08/2019 (21:16:32)

BRIEF DESCRIPTION

CC, breast or GYN ca, post definitive therapy, post menopausal, effects of bupropion on sexual desire.  DCP-001 Eligible






SWOG S1501 - "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III"

CANCER TYPE: Breast
RESEARCH BASE: SWOG
NCT NUMBER: NCT03418961
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 11/20/2018 (19:47:17)

BRIEF DESCRIPTION

Stage IV breast ca, at increased risk for cardiotoxicity, starting or currently taking trastuzumab based HER-2 targeted therapy, carvedilol vs. observation.  DCP-001 Eligible






URCC-16070 - "Treatment of Refractory Nausea"

CANCER TYPE: Breast
RESEARCH BASE: URCC
NCT NUMBER: NCT03367572
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 02/22/2019 (20:58:18)

BRIEF DESCRIPTION

Nausea in breast ca patients receiving chemo, netupitant/palonosetron + dexamethasone +/- prochlorperazine or olanzapine.






Wake Forest WF 97116 - "A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment"

CANCER TYPE: Breast
RESEARCH BASE: Wake Forest
NCT NUMBER: NCT02822573
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 09/05/2018 (19:11:21)

BRIEF DESCRIPTION

Breast ca survivors with cognitive impairment after chemotherapy, donepezil vs. placebo.  DCP-001 Eligible






Wake Forest WF-97415 - "Understanding and Predicting Breast Cancer Events after Treatment (UPBEAT)"

CANCER TYPE: Breast
RESEARCH BASE: Wake Forest
NCT NUMBER: NCT02791581
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 07/27/2018 (16:09:41)

BRIEF DESCRIPTION

Cancer control, stage I-III female breast ca, will receive neo-adj or adj chemo +/- RT, determine risk for long term left ventricular dysfunction, exercise intolerance, progressive fatigue and CV events. 

DCP-001 Eligible






GI

SWOG S0820 - "A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)".

CANCER TYPE: GI
RESEARCH BASE: SWOG S0820
NCT NUMBER: 01349881
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 11/07/2018 (21:09:40)

BRIEF DESCRIPTION

Colorectal, prior Stg 0-III w/resection alone or in combination with radiation or chemotherapy, NED, Placebo-controlled Eflornithine & Sulindac to prevent high-risk adenoma & 2nd prim recurrence.  DCP-001 Eligible






URCC 16092 - "Phase II Study of Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy"

CANCER TYPE: GI
RESEARCH BASE: URCC
NCT NUMBER: NCT03186638
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 02/22/2019 (22:16:03)

BRIEF DESCRIPTION

Cognitive impairment prevention in non-metastatic colorectal cancer, post resection, currently receiving adj chemo, 6 weeks of 200 mg BID ibuprofen or placebo.  DCP-001 Eligible






GU

SWOG S1600 - "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes."

CANCER TYPE: GU
RESEARCH BASE: SWOG
NCT NUMBER:
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 02/26/2019 (17:58:44)

BRIEF DESCRIPTION

Immune enhancing nutrition for patients undergoing radical cystectomy for primary cell carcinoma of the bladder.  No mets, must be resectable disease.






GYN

NRG-CC004 - "PHASE II DOUBLE BLIND DOSE FINDING TRIAL OF BUPROPION VERSUS PLACEBO FOR SEXUAL DESIRE IN WOMEN WITH BREAST OR GYNECOLOGIC CANCER"

CANCER TYPE: GYN
RESEARCH BASE: NRG
NCT NUMBER: NCT03180294
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 03/08/2019 (21:17:03)

BRIEF DESCRIPTION

CC, breast or GYN ca, post definitive therapy, post menopausal, effects of bupropion on sexual desire. DCP-001 Eligible






Leukemia

ECOG-ACRIN EA9131 - "A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)"

CANCER TYPE: Leukemia
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT03253848
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 08/16/2018 (20:47:54)

BRIEF DESCRIPTION

To evaluate if the proposed patient care strategy, that includes use of simplified Guidelines along with APL expert support, decreases the one-month induction mortality rate from 30% to under 15%.  DCP-001 Eligible






MDS

NHLBI-MDS "The National Myelodysplastic Syndromes (MDS) Study"

CANCER TYPE: MDS
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT02775383
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 02/13/2019 (21:35:23)

BRIEF DESCRIPTION

Collect clinical data and biological specimens in order to develop databases to support MDS studies.  DCP-001 Eligible









  © 2013-2019 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA